Randomized Trial Comparing Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF) Regimen with Rotational CMFEV Regimen (E=Epirubicin, V=Vincristine) as Adjuvant Chemotherapy in Moderate Risk Operable Breast Carcinoma


Objectives: The CMFEV (cyclophosphamide, methotrexate, 5-fluorouracil, epirubicin, vincristine) regimen is an innovative schedule, designed by our Group, aimed at administering five partially or totally no cross-resistant cytotoxic agents in breast carcinoma. It was randomly compared to CMF (cyclophosphamide, methotrexate, 5-fluorouracil) as primary treatment in operable disease and demonstrated a short-term significant increase in clinical complete response rate and a long-term significant locoregional relapse-free survival in premenopausal patients. So, it seemed worth comparing this regimen with CMF as adjuvant chemotherapy in moderate risk operable breast carcinoma. Methods: Four hundred and eighty-nine patients with stage I or II moderate risk breast carcinoma were randomized to receive CMF or CMFEV regimen for 6 cycles after surgery. Main end points were overall survival (OS), invasive disease-free survival (IDFS) and recurrence-free interval (RFI), as estimated by Kaplan-Meier analyses and log-rank tests. Results: At a median observation time of 7.3 years (range 5.4 months-10.3 years), no significant differences in OS and IDFS were observed between the two arms. Deaths from breast carcinoma were more frequent with CMF (58.5%) than with CMFEV regimen (41.7%) as well as recurrences from breast carcinoma (58.8% with CMF and 41.2% with CMFEV). These differences were not statistically significant. Conclusion: CMFEV appears more effective than CMF in preventing recurrences from primary disease in patients with moderate risk stage I-II breast carcinoma. The lack of statistical significance of the observed differences was probably due to the limited number of patients enrolled which rendered the study underpowdered.

Share and Cite:

G. Cocconi, C. Boni, M. Tonato, R. Passalacqua, M. Colozza, A. Mosconi, G. Bisagni, E. Rondini, L. Rodinò, A. Carpi, F. Costanzo, M. Brugia, G. Attardo, L. Acito, R. Rossetti, M. Bella, R. Camisa, F. Cardinale and B. Dozin, "Randomized Trial Comparing Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF) Regimen with Rotational CMFEV Regimen (E=Epirubicin, V=Vincristine) as Adjuvant Chemotherapy in Moderate Risk Operable Breast Carcinoma," Journal of Cancer Therapy, Vol. 2 No. 3, 2011, pp. 342-353. doi: 10.4236/jct.2011.23047.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Early Breast Cancer Trialists’ Collaborative Group, “Effect of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials,” Lancet, Vol. 365, No. 9472, 2005, pp. 1687-1717. doi:10.1016/S0140-6736(05)66544-0
[2] G. Bonadonna, E. Brusamolino, P. Valagussa, A. Rossi, L. Brugnatelli, C. Brambilla, M. De Lena, G. Tancini, E. Bajetta, R. Musumeci and U. Veronesi, “Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer,” The New England Journal of Medicine, Vol. 294, No. 8, 1976, pp. 405-410. doi:10.1056/NEJM197602192940801
[3] G. Bonadonna, A. Moliterni, M. Zambetti, M. G. Dandone, S. Pilotti, L. Gianni and P. Valagussa, “30 Years’ Follow up of Randomised Studies of Adjuvant CMF in Operable Breast Cancer: Cohort Study,” British Medicine Journal, Vol. 330, No. 7485, 2005, pp. 205-206. doi:10.1136/bmj.38314.622095.8F
[4] Early Breast Cancer Trialists Collaborative Group, “Polychemotherapy for Early Breast Cancer: An Overview of Randomised Trials,” Lancet, Vol. 352, No. 9132, 1998, No. 9132, pp. 930-942. doi:10.1016/S0140-6736(98)03301-7
[5] G. Cocconi, “Adjuvant Chemotherapy in Early Breast Cancer: Optimal and Suboptimal Anthracycline Containig Regimens,” Breast Cancer Research and Treatment, Vol. 80, No. 3, 2003, pp. 313-320. doi:10.1023/A:1024955408785
[6] R. B Weiss, D. C.Tormey, F. Holland, V. E. Weinberg, G. Lesnick, M. Perloff, G. Falkson and O. J. Glidewell, “A Randomised Trial of Postoperative Five-versus Three Drug Chemotherapy after Mastectomy; A Cancer and Leukemia Group B (CALGB) Study,” Recent Results Cancer Research, Vol. 80, No. 1, 1982, pp. 170-176.
[7] D. C. Tormey, V. E. Weinberg, J. F. Holland, R. B. Weiss, O. J. Glidewell, M. Perloff, G. Falson, H. C. Falkson, P. H. Henry and L. A. Leone, “A Randomised Trial of Five and Three Drug Chemotherapy and Chemo-Immunotherapy in Women with Operable Node Positive Breast Cancer. A CALGB Study,” Journal of Clinical Oncology, Vol. 1, No. 2, 1983, pp. 138-145.
[8] L. Gianni, J. Baselga, W, Elemann, V. G. Porta, V. Semi- glazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. L. Cussac, A. Bozhok, A. Martinez-Agullo, et al., “Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclo-phosphamide, Methotrexate, and Fluorouracil, as Adjuvant or Primary Systemic Therapy European Cooperative Trial in Operable Breast Cancer,” Journal of Clinical Oncology, Vol. 27, No. 15, 2009, pp. 2474-2481. doi:10.1200/JCO.2008.19.2567
[9] G. Cocconi, G. Bisagni, M. Bacchi, F. Buzzi, R. Canaletti, A. Carpi, G. Ceci, A. Colozza, V. De Lisi and R. Lottici “A Comparison of Continuation versus Late Intensification Followed by Discontinuation of Chemotherapy in Advanced Breast Cancer. A Prospective Randomized Trial of the Italian Oncology Group for Clinical Research (GOIRC),” Annals of Oncology, Vol. 1, No. 1, 1990, pp. 36-44.
[10] G. Cocconi, B. Di Blasio, C. Boni, G. Bisagniu, G. Ceci, E. Rondini, M. Bella, F. Leonardi, L. Savoldi, R. Camisa and P. Bruzzi, “Randomized Trial Comparing Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF) with Rotational CMF, Epirubicin and Vincristine as Primary Chemotherapy in Operable Breast Cancer,” Cancer, Vol. 95, No. 2, 2002, pp. 228-235. doi:10.1002/cncr.10678
[11] G. Cocconi, B. Di Blasio, C. Boni, G. Bisagni, G. Ceci, E. Rondini, M. Bella, F. Leonardi, L. Savoldi, C. Vallisneri, R. Camisa and P. Bruzzi, “Primary Chemotherapy in Operable Breast Carcinoma Comparing CMF (Cyclophosphamide, Methotreaxate, 5-Fluorouracil) with an Anthracycline Containing Regimen: Short-Term Responses Translated into Long-Term Outcomes,” Annals of On- cology, Vol. 16, No. 9, 2005, pp. 1469-1476. doi:10.1093/annonc/mdi278
[12] A. B. Miller, R. Hoogstraten, M. Staquet and A. Winkler, “Reporting Results of Cancer Treatment,” Cancer, Vol. 47, No. 1, 1981, pp. 207-214. doi:10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
[13] C. A. Hudis, W. E. Barlow, J. P. Costantino, R. J. Gray, K. I. Pritchard, J. W. Chapman, J. A. Sparano, S. Hunsberger, R. A. Enos, R. D. Gelber and J. O. Zujewski, “Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System,” Journal of Clinical Oncology, Vol. 25, No. 15, 2007, pp. 2127-2132. doi:10.1200/JCO.2006.10.3523
[14] E. L. Kaplan and P. Meier, “Nonparametric Estimation from Incomplete Observations,” Journal of the American Statistical Association, Vol. 53, No. 282, 1958, pp. 457-481. doi:10.2307/2281868
[15] D. R. Cox, “The Regression Analysis of Binary Sequences,” Journal of the Royal Statistical Society, Vol. 20, No. 2, 1958, pp. 215-242.
[16] J. Cuzick, “Forest Plots and the Interpretation of Subgroups,” Lancet, Vol. 365, No. 9467, 2005, p. 1308. doi:10.1016/S0140-6736(05)61026-4
[17] B. Fisher, A. M. Brown, N. V. Dimitrov, R. Poisson, C. Redmond, R. G. Margolese, D. Bowman, N. Wolmark, D. L. Wickerham, et al., “Two Months of Doxorubicin-Cyclophosphamide with and without Reinduction Therapy Compared with 6 Months of Cyclophosphamide, Methotrexate, and Fluo- rouracil in Positive-Node Breast Cancer Patients with Tamoxifen Non-responsive Tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15,” Journal of Clinical Oncology, Vol. 8, No. 9, 1990, pp. 1483-1496.
[18] B. Fisher, S. Anderson, Chiu-Tan, N. Wolmark, D. L. Wickerham, E. R. Fisher, N. V. Dimitrov, J. N. Atkins, N. Abramson, S. Merajver, E. H. Romon, C. G. Kardinakl, et al., “Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23,” Journal of Clinical Oncology, Vol. 19, No. 4, 2001, pp. 931-942.
[19] M. Martin, A. Villar, A. Sole-Calvo, R. Gonzalez, B. Massuti, J. Lizon, C. Camps, A. Carrato, et al., “Doxorubicin in Combination with Fluorouracil and Cyclophosphamide (i.v. FAC Regimen day 1, 21) versus Methotrexate in Combination with Fluorouracil and Cyclophosphamide (i.v. CMF Regimen, day 1, 21) as Adjuvant Chemotherapy for Operable Breast Cancer: A Study of the GEICAM Group,” Annals of Oncology, Vol. 14, No. 6, pp. 833-842. doi:10.1093/annonc/mdg260
[20] H. T. Mouridsen, J. Andersen, M. Andersson, P. Dombernowsky, B. Ejilertsen, C, Rose, P. G. Sorensen, E. Sandberg, K. W. Andersen, M. B. Jensen, N. O. Bengston, J. Bergh and B. Nordenskjold, “Adjuvant Anthracycline in Breast Cancer Improves Outcome in Premenopausal Patients Following Substitution of Methotrexate in the CMF Combination with Epirubicin,” Proceed ASCO, Vol. 18, No. 68, 1999, p. 19.
[21] P. Francis, J. Crown, A. Di Leo, M. Buyse, A. Balil, M. Andersson, B. Nordenskjold, I. Lang, R. Jakesz, D. Vorobiof, J. Gutierrez, G. van Hazel, S. Dolci, S. Jamin, B. Bendahmane, R. D. Gelber, M. Castiglione-Gerstsch and M. Piccart-Gebhart, “Adjuvant Chemotherapy with Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02-98 Randomized Trial,” Journal of National Cancer Institution, Vol. 100, No. 2, 2008, pp. 121-133. doi:10.1093/jnci/djm287
[22] J. M. Albert, A. U. Budzar, R. Guzman, P. K. Allen, E. A. Strom, G. H. Perkins, W. A. Woodward, K. E. Hoffman, W. Tereffe, K. K. Hunt, T. A. Buchholz and G. L. Oh, “Prospective Randomized Trial of 5-Fluorouracil, Doxo-rubicin, and Cyclophosphamide (FAC) versus Paclitaxel and FAC (TFAC) in Patients with Operable Breast Cancer: Impact of Taxane Chemotherapy on Locoregional Control,” Breast Cancer Research and Treatment, Vol. 128, No. 2, 2011, pp. 421-427.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.